These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 2876654)

  • 1. Can drugs be used to enhance the psychotherapeutic process?
    Grinspoon L; Bakalar JB
    Am J Psychother; 1986 Jul; 40(3):393-404. PubMed ID: 2876654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychedelic and entactogenic drugs in the treatment of depression.
    Riedlinger TJ; Riedlinger JE
    J Psychoactive Drugs; 1994; 26(1):41-55. PubMed ID: 7913128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychedelics and Psychedelic-Assisted Psychotherapy.
    Reiff CM; Richman EE; Nemeroff CB; Carpenter LL; Widge AS; Rodriguez CI; Kalin NH; McDonald WM;
    Am J Psychiatry; 2020 May; 177(5):391-410. PubMed ID: 32098487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
    Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W
    Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Psychotherapy with Adjuvant use of Serotonergic Psychoactive Substances: Possibilities and Challenges].
    Majić T; Jungaberle H; Schmidt TT; Zeuch A; Hermle L; Gallinat J
    Fortschr Neurol Psychiatr; 2017 Jul; 85(7):383-392. PubMed ID: 28768346
    [No Abstract]   [Full Text] [Related]  

  • 6. Acute subjective effects in LSD- and MDMA-assisted psychotherapy.
    Schmid Y; Gasser P; Oehen P; Liechti ME
    J Psychopharmacol; 2021 Apr; 35(4):362-374. PubMed ID: 33853422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Why MDMA therapy for alcohol use disorder? And why now?
    Sessa B
    Neuropharmacology; 2018 Nov; 142():83-88. PubMed ID: 29126911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in the stimulus properties of 3,4-methylenedioxyamphetamine and 3,4- methylenedioxymethamphetamine in animals trained to discriminate hallucinogens from saline.
    Callahan PM; Appel JB
    J Pharmacol Exp Ther; 1988 Sep; 246(3):866-70. PubMed ID: 2901488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychedelic drugs-a new era in
psychiatry?
.
    Nutt D
    Dialogues Clin Neurosci; 2019; 21(2):139-147. PubMed ID: 31636488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dark Classics in Chemical Neuroscience: Lysergic Acid Diethylamide (LSD).
    Nichols DE
    ACS Chem Neurosci; 2018 Oct; 9(10):2331-2343. PubMed ID: 29461039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there a case for MDMA-assisted psychotherapy in the UK?
    Sessa B
    J Psychopharmacol; 2007 Mar; 21(2):220-4. PubMed ID: 17329304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increasing use of "Ecstasy" (MDMA) and other hallucinogens on a college campus.
    Cuomo MJ; Dyment PG; Gammino VM
    J Am Coll Health; 1994 May; 42(6):271-4. PubMed ID: 7913938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of recreational psychedelic substance use experiences classified by substance.
    Hase A; Erdmann M; Limbach V; Hasler G
    Psychopharmacology (Berl); 2022 Feb; 239(2):643-659. PubMed ID: 35031816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Turn on and tune in to evidence-based psychedelic research.
    Sessa B
    Lancet Psychiatry; 2015 Jan; 2(1):10-2. PubMed ID: 26359597
    [No Abstract]   [Full Text] [Related]  

  • 15. Nothing Ventured, Nothing Gained: Regulations Cripple Potentially Life-Saving Research of Illicit Substances.
    Abbott KL; Gill KS; Flannery PC; Boothe DM; Dhanasekaran M; Pondugula SR
    ACS Chem Neurosci; 2020 May; 11(10):1382-1384. PubMed ID: 32395981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychedelic drugs: the ups and downs of ecstasy.
    Check E
    Nature; 2004 May; 429(6988):126-8. PubMed ID: 15141183
    [No Abstract]   [Full Text] [Related]  

  • 17. Progress and promise for the MDMA drug development program.
    Feduccia AA; Holland J; Mithoefer MC
    Psychopharmacology (Berl); 2018 Feb; 235(2):561-571. PubMed ID: 29152674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner.
    Lyvers M; Meester M
    J Psychoactive Drugs; 2012; 44(5):410-7. PubMed ID: 23457892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Compassionate use of psychedelics.
    Greif A; Šurkala M
    Med Health Care Philos; 2020 Sep; 23(3):485-496. PubMed ID: 32468195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prohibited or regulated? LSD psychotherapy and the United States Food and Drug Administration.
    Oram M
    Hist Psychiatry; 2016 Sep; 27(3):290-306. PubMed ID: 27194113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.